Matches in Nanopublications for { ?s ?p "[On the basis of preclinical data suggesting synergy of HER2 inhibition and mTOR inhibition in breast and lung cancer models, we conducted a phase I combination study of neratinib, a small-molecule irreversible pan-HER tyrosine kinase inhibitor, and temsirolimus, an mTOR inhibitor, in patients with advanced solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- assertion description "[On the basis of preclinical data suggesting synergy of HER2 inhibition and mTOR inhibition in breast and lung cancer models, we conducted a phase I combination study of neratinib, a small-molecule irreversible pan-HER tyrosine kinase inhibitor, and temsirolimus, an mTOR inhibitor, in patients with advanced solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[On the basis of preclinical data suggesting synergy of HER2 inhibition and mTOR inhibition in breast and lung cancer models, we conducted a phase I combination study of neratinib, a small-molecule irreversible pan-HER tyrosine kinase inhibitor, and temsirolimus, an mTOR inhibitor, in patients with advanced solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[On the basis of preclinical data suggesting synergy of HER2 inhibition and mTOR inhibition in breast and lung cancer models, we conducted a phase I combination study of neratinib, a small-molecule irreversible pan-HER tyrosine kinase inhibitor, and temsirolimus, an mTOR inhibitor, in patients with advanced solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP379968.RARlNpk-sBwR1T3oFKTNzh1QFfHAtX8dVY6xhztB-EgVQ130_assertion description "[On the basis of preclinical data suggesting synergy of HER2 inhibition and mTOR inhibition in breast and lung cancer models, we conducted a phase I combination study of neratinib, a small-molecule irreversible pan-HER tyrosine kinase inhibitor, and temsirolimus, an mTOR inhibitor, in patients with advanced solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP379968.RARlNpk-sBwR1T3oFKTNzh1QFfHAtX8dVY6xhztB-EgVQ130_provenance.
- NP1135291.RApbsVbv1102UVDjhgaD4v-AIi6PumiSbiMJF1aMCubu4130_assertion description "[On the basis of preclinical data suggesting synergy of HER2 inhibition and mTOR inhibition in breast and lung cancer models, we conducted a phase I combination study of neratinib, a small-molecule irreversible pan-HER tyrosine kinase inhibitor, and temsirolimus, an mTOR inhibitor, in patients with advanced solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1135291.RApbsVbv1102UVDjhgaD4v-AIi6PumiSbiMJF1aMCubu4130_provenance.
- NP379524.RAJ9_09fe4rsYi8PR_IeTLBZr-wwCj7VQv0r6gId-ksgI130_assertion description "[On the basis of preclinical data suggesting synergy of HER2 inhibition and mTOR inhibition in breast and lung cancer models, we conducted a phase I combination study of neratinib, a small-molecule irreversible pan-HER tyrosine kinase inhibitor, and temsirolimus, an mTOR inhibitor, in patients with advanced solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP379524.RAJ9_09fe4rsYi8PR_IeTLBZr-wwCj7VQv0r6gId-ksgI130_provenance.
- NP1135290.RAx22z0QD7Ex3JxMxZccPTpv744R19v82FtsChXtbp9bc130_assertion description "[On the basis of preclinical data suggesting synergy of HER2 inhibition and mTOR inhibition in breast and lung cancer models, we conducted a phase I combination study of neratinib, a small-molecule irreversible pan-HER tyrosine kinase inhibitor, and temsirolimus, an mTOR inhibitor, in patients with advanced solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1135290.RAx22z0QD7Ex3JxMxZccPTpv744R19v82FtsChXtbp9bc130_provenance.